Drug profile

The FDA adverse-event record for Anti-Il31 Mab Mcs Lot #1283563

5,270 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Anti-Il31 Mab Mcs Lot #1283563. See the species affected, top reactions, and outcomes below.

5,270
adverse-event reports
6.8%
death-coded share
Dog
most-reported species
994
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
5,270
Total Reports
360
Deaths Reported
6.8%
Death Rate

Active Ingredients

Anti-Il31 Mab Mcs Lot #1283563

Administration Routes

SubcutaneousUnknownOtherOralSubconjunctivalSublingualIntramuscularAuricular (Otic)Intrathoracic

Species Affected

Dog 5,268
Cat 2

Most Affected Breeds

Retriever - Labrador 436
Terrier - Bull - American Pit 314
Terrier - Yorkshire 291
Shih Tzu 272
Bulldog - French 244
Chihuahua 222
Retriever - Golden 197
Shepherd Dog - German 187
Crossbred Canine/dog 170
Boxer (German Boxer) 149

Most Reported Reactions

Vomiting 994
Lack of efficacy - NOS 833
INEFFECTIVE, ATOPY CONTROL 751
Lethargy (see also Central nervous system depression in 'Neurological') 632
Diarrhoea 535
Anorexia 303
Lethargy (see also Central nervous system depression in Neurological) 275
Hives (see also 'Skin') 273
Seizure NOS 257
Not eating 248
Decreased appetite 217
Pruritus 213

Outcome Breakdown

Ongoing
3,548 (67.3%)
Recovered/Normal
757 (14.4%)
Outcome Unknown
597 (11.3%)
Euthanized
194 (3.7%)
Died
166 (3.1%)
Recovered with Sequela
11 (0.2%)

Anti-Il31 Mab Mcs Lot #1283563 Adverse Event Insights

5,270 reports name Anti-Il31 Mab Mcs Lot #1283563; 360 recorded a death outcome (6.8% of reported events, not a population-level mortality rate). Active ingredient: Anti-Il31 Mab Mcs Lot #1283563. Administration routes: Subcutaneous, Unknown, Other, Oral.

By species: Dog (5,268 reports), Cat (2 reports). By breed: Retriever - Labrador (436), Terrier - Bull - American Pit (314), Terrier - Yorkshire (291).

Leading clinical signs: Vomiting (994), Lack of efficacy - NOS (833), INEFFECTIVE, ATOPY CONTROL (751), Lethargy (see also Central nervous system depression in 'Neurological') (632). Outcome, 5,273 coded reports: Ongoing leads at 67.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.